Sign in or create an account to add this stock to your watchlist.
About Teladoc (NYSE:TDOC)
Teladoc, Inc. provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone. It serves employers of Fortune 1000 companies, health plans, health systems, and other entities. Teladoc, Inc. was founded in 2002 and is headquartered in Purchase, New York.
Industry, Sector and Symbol
Industry Offices & clinics of medical doctors
Sub-IndustryN/A
SectorMedical
SymbolNYSE:TDOC
CUSIPN/A
Phone203-635-2002
Debt
Debt-to-Equity Ratio0.38
Current Ratio4.15
Quick Ratio4.15
Price-To-Earnings
Trailing P/E Ratio-29.91
Forward P/E Ratio-36.02
P/E GrowthN/A
Sales & Book Value
Annual Sales$233.28 million
Price / Sales13.19
Cash FlowN/A
Price / CashN/A
Book Value$8.84 per share
Price / Book5.58
Profitability
EPS (Most Recent Fiscal Year)($1.65)
Net Income$-106,780,000.00
Net Margins-41.06%
Return on Equity-20.40%
Return on Assets-12.48%
Miscellaneous
Employees1,231
Outstanding Shares62,330,000
Teladoc (NYSE:TDOC) Frequently Asked Questions
What is Teladoc's stock symbol?
Teladoc trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC."
How were Teladoc's earnings last quarter?
Teladoc (NYSE:TDOC) announced its quarterly earnings results on Tuesday, May, 1st. The health services provider reported ($0.39) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.04. The health services provider earned $89.64 million during the quarter, compared to analysts' expectations of $86.77 million. Teladoc had a negative net margin of 41.06% and a negative return on equity of 20.40%. The company's revenue was up 109.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.30) EPS. View Teladoc's Earnings History.
What guidance has Teladoc issued on next quarter's earnings?
Teladoc updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided EPS guidance of ($1.41-1.36) for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($1.35). The company issued revenue guidance of $350-360 million, compared to the consensus revenue estimate of $356.28 million.Teladoc also updated its Q2 guidance to ($0.37-0.35) EPS.
What price target have analysts set for TDOC?
16 brokerages have issued twelve-month price targets for Teladoc's shares. Their predictions range from $35.00 to $50.00. On average, they expect Teladoc's stock price to reach $43.00 in the next year. View Analyst Ratings for Teladoc.
What are Wall Street analysts saying about Teladoc stock?
Here are some recent quotes from research analysts about Teladoc stock:
- 1. Cantor Fitzgerald analysts commented, "4Q17 in line or slightly better than expected. Revenue was $77 million vs. our estimate and FactSet of consensus of $76 million. Visits grew 49%. PMPM was $0.95 vs. $0.91 in 3Q17. Gross margin declined y/y given the expected revenue shift. TDOC reported positive adjusted EBITDA of $2.4M vs FactSet $2.5M. GAAP EPS included several non-recurring/non-cash items. Overall, we believe that TDOC had a strong quarter." (2/27/2018)
- 2. According to Zacks Investment Research, "The stock of Teladoc has outperformed the industry year to date. The company is witnessing steady business growth with insurers and customers increasingly embracing telehealth. It’s organic growth initiative remains on track. With a number of acquisitions completed since its inception, the company has expanded its distribution capabilities and broadened its service offering. Also the company boasts an impressive clientele. The company has also provided strong guidance for 2017. The company has incurred significant losses in each period since its inception in 2002. Teladoc has been unable to generate cash from operations and we have doubts over its ability to do so in the coming quarters. Its high debt level has caused a spike in interest expense which has dented its operating margins." (10/18/2017)
Who are some of Teladoc's key competitors?
Some companies that are related to Teladoc include Teleflex (TFX), Olympus (OCPNY), DaVita (DVA), Genmab (GNMSF), Aegon (AGN), Smith & Nephew (SN), The Cooper Companies (COO), Universal Health Services (UHS), Henry Schein (HSIC), Cochlear (COH), Varian Medical Systems (VAR), Dentsply Sirona (XRAY), Straumann (SAUHF), Hologic (HOLX) and Sonova (SONVY).
Who are Teladoc's key executives?
Teladoc's management team includes the folowing people:
- Mr. Jason Gorevic, CEO & Director (Age 46)
- Mr. Peter A. McClennen, Pres (Age 49)
- Mr. Mark J. Hirschhorn, Chief Financial Officer, Chief Operating Officer and Exec. VP (Age 53)
- Mr. Adam C. Vandervoort, Chief Legal Officer and Sec. (Age 43)
- Mr. Michael King, Chief Sales Officer (Age 55)
When did Teladoc IPO?
(TDOC) raised $112 million in an initial public offering (IPO) on Wednesday, July 1st 2015. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.
Has Teladoc been receiving favorable news coverage?
Media coverage about TDOC stock has been trending somewhat negative this week, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Teladoc earned a news impact score of -0.08 on Accern's scale. They also gave news headlines about the health services provider an impact score of 44.43 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Teladoc's major shareholders?
Teladoc's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.83%), JPMorgan Chase & Co. (7.51%), Eagle Asset Management Inc. (3.90%), Bamco Inc. NY (3.11%), Zevenbergen Capital Investments LLC (2.52%) and Global Thematic Partners LLC (2.05%). Company insiders that own Teladoc stock include Adam C Vandervoort, Andrew Turitz, James K Outland, Jason N Gorevic, Lp Chp III, Mark Hirschhorn, Michael Goldstein, Michael H King, Peter A Mcclennen and Trident Capital Fund Vi Lp. View Institutional Ownership Trends for Teladoc.
Which institutional investors are selling Teladoc stock?
TDOC stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Hood River Capital Management LLC, BlackRock Inc., Prudential Financial Inc., Tiverton Asset Management LLC, Loomis Sayles & Co. L P, Great West Life Assurance Co. Can and RMB Capital Management LLC. Company insiders that have sold Teladoc company stock in the last year include Adam C Vandervoort, Andrew Turitz, Jason N Gorevic, Mark Hirschhorn, Michael Goldstein and Peter A Mcclennen. View Insider Buying and Selling for Teladoc.
Which institutional investors are buying Teladoc stock?
TDOC stock was purchased by a variety of institutional investors in the last quarter, including Global Thematic Partners LLC, Bellevue Group AG, Millennium Management LLC, Baillie Gifford & Co., Redmile Group LLC, Wells Fargo & Company MN, D L Carlson Investment Group Inc. and IFP Advisors Inc. View Insider Buying and Selling for Teladoc.
How do I buy shares of Teladoc?
Shares of TDOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teladoc's stock price today?
One share of TDOC stock can currently be purchased for approximately $49.35.
How big of a company is Teladoc?
Teladoc has a market capitalization of $3.08 billion and generates $233.28 million in revenue each year. The health services provider earns $-106,780,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Teladoc employs 1,231 workers across the globe.
How can I contact Teladoc?
Teladoc's mailing address is 2 MANHATTANVILLE ROAD SUITE 203, PURCHASE NY, 10577. The health services provider can be reached via phone at 203-635-2002 or via email at [email protected]
MarketBeat Community Rating for Teladoc (TDOC)
MarketBeat's community ratings are surveys of what our community members think about Teladoc and other stocks. Vote "Outperform" if you believe TDOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TDOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Teladoc (NYSE:TDOC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
16 Wall Street analysts have issued ratings and price targets for Teladoc in the last 12 months. Their average twelve-month price target is $43.00, suggesting that the stock has a possible downside of 12.87%. The high price target for TDOC is $50.00 and the low price target for TDOC is $35.00. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.80 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $43.00 | $41.9286 | $39.5385 | $39.0909 |
| Price Target Upside: | 12.87% downside | 1.89% upside | 4.32% upside | 24.10% upside |
Teladoc (NYSE:TDOC) Consensus Price Target History
Teladoc (NYSE:TDOC) Analyst Ratings History
Show:
(Data available from 5/20/2016 forward)
Teladoc (NYSE:TDOC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Teladoc (NYSE TDOC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.95%
Teladoc (NYSE TDOC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/15/2018 | Jason N Gorevic | CEO | Sell | 25,000 | $48.93 | $1,223,250.00 | 636,184 |  |
| 5/2/2018 | Mark Hirschhorn | VP | Sell | 69,460 | $43.73 | $3,037,485.80 | 50,042 | |
| 4/16/2018 | Jason N Gorevic | CEO | Sell | 25,000 | $41.36 | $1,034,000.00 | 661,184 | |
| 3/12/2018 | Jason N Gorevic | CEO | Sell | 40,000 | $43.27 | $1,730,800.00 | | |
| 3/7/2018 | Peter A. Mcclennen | President | Sell | 27,533 | $43.01 | $1,184,194.33 | | |
| 3/6/2018 | Andrew Turitz | SVP | Sell | 36,210 | $40.39 | $1,462,521.90 | 16,700 | |
| 3/5/2018 | Adam C Vandervoort | Insider | Sell | 47,123 | $39.36 | $1,854,761.28 | 19,338 | |
| 3/2/2018 | Adam C Vandervoort | Insider | Sell | 27,809 | $38.62 | $1,073,983.58 | 19,338 | |
| 3/2/2018 | Andrew Turitz | SVP | Sell | 19,245 | $39.25 | $755,366.25 | 16,700 | |
| 3/2/2018 | Michael Goldstein | Director | Sell | 66,574 | $39.72 | $2,644,319.28 | 54,325 | |
| 2/28/2018 | Mark Hirschhorn | CFO | Sell | 100,000 | $39.60 | $3,960,000.00 | 98,960 | |
| 12/4/2017 | Jason N Gorevic | CEO | Sell | 100,000 | $32.99 | $3,299,000.00 | 718,261 | |
| 12/4/2017 | Mark Hirschhorn | CFO | Sell | 30,000 | $32.99 | $989,700.00 | 5,203 | |
| 11/2/2017 | Jason N Gorevic | CEO | Sell | 20,000 | $32.10 | $642,000.00 | 838,261 | |
| 10/17/2017 | Mark Hirschhorn | VP | Sell | 35,000 | $32.84 | $1,149,400.00 | 20,887 | |
| 10/16/2017 | Mark Hirschhorn | CFO | Sell | 25,000 | $32.37 | $809,250.00 | 20,887 | |
| 10/2/2017 | Jason N Gorevic | CEO | Sell | 20,000 | $33.47 | $669,400.00 | | |
| 10/2/2017 | Mark Hirschhorn | VP | Sell | 10,000 | $34.04 | $340,400.00 | | |
| 9/22/2017 | Mark Hirschhorn | VP | Sell | 25,000 | $31.93 | $798,250.00 | 64,987 | |
| 8/7/2017 | Adam C Vandervoort | Insider | Sell | 53,806 | $30.92 | $1,663,681.52 | 33,008 | |
| 6/6/2017 | Jason N Gorevic | CEO | Sell | 19,991 | $32.89 | $657,503.99 | 831,650 | |
| 6/5/2017 | Jason N Gorevic | CEO | Sell | 13,389 | $32.89 | $440,364.21 | 831,650 | |
| 5/25/2017 | Jason N Gorevic | CEO | Sell | 5,600 | $29.57 | $165,592.00 | 823,861 | |
| 5/23/2017 | Jason N Gorevic | CEO | Sell | 14,400 | $29.57 | $425,808.00 | 822,961 | |
| 5/17/2017 | Mark Hirschhorn | VP | Sell | 100,000 | $27.70 | $2,770,000.00 | 80,887 | |
| 5/8/2017 | Jason N Gorevic | CEO | Sell | 15,000 | $23.11 | $346,650.00 | 833,261 | |
| 4/19/2017 | Mark Hirschhorn | VP | Sell | 59,100 | $25.46 | $1,504,686.00 | 180,887 | |
| 4/19/2017 | Michael H King | Insider | Sell | 5,000 | $25.75 | $128,750.00 | 61,459 | |
| 1/26/2017 | Mark Hirschhorn | VP | Sell | 900 | $20.00 | $18,000.00 | 239,987 | |
| 1/24/2017 | Jason N Gorevic | CEO | Sell | 100,000 | $15.79 | $1,579,000.00 | 926,158 | |
| 1/24/2017 | Trident Capital Fund Vi Lp | Major Shareholder | Sell | 250,000 | $15.79 | $3,947,500.00 | | |
| 1/19/2017 | Michael H King | Insider | Sell | 5,000 | $19.00 | $95,000.00 | 66,459 | |
| 1/17/2017 | Mark Hirschhorn | VP | Sell | 10,000 | $17.84 | $178,400.00 | 240,887 | |
| 1/9/2017 | Mark Hirschhorn | VP | Sell | 5,000 | $17.50 | $87,500.00 | 250,887 | |
| 12/15/2016 | Mark Hirschhorn | VP | Sell | 5,000 | $16.60 | $83,000.00 | 255,887 | |
| 12/14/2016 | Lp Chp III | Major Shareholder | Sell | 500,000 | $16.36 | $8,180,000.00 | | |
| 11/16/2016 | Mark Hirschhorn | VP | Sell | 10,000 | $17.19 | $171,900.00 | 258,387 | |
| 11/10/2016 | Mark Hirschhorn | VP | Sell | 5,000 | $17.50 | $87,500.00 | 267,687 | |
| 10/17/2016 | Mark Hirschhorn | VP | Sell | 5,000 | $15.52 | $77,600.00 | 268,387 | |
| 8/16/2016 | Jason N Gorevic | CEO | Sell | 40,000 | $17.92 | $716,800.00 | 967,258 | |
| 8/11/2016 | Michael H King | Insider | Sell | 25,000 | $17.20 | $430,000.00 | 91,459 | |
| 8/8/2016 | Adam C Vandervoort | Insider | Sell | 52,865 | $16.64 | $879,673.60 | 46,685 | |
| 8/2/2016 | James K Outland | Director | Sell | 10,000 | $18.00 | $180,000.00 | 49,089 | |
| 7/15/2016 | Jason N Gorevic | CEO | Sell | 5,000 | $15.45 | $77,250.00 | 932,258 | |
| 6/29/2016 | James K Outland | Director | Sell | 10,000 | $15.00 | $150,000.00 | 59,089 | |
| 6/29/2016 | Jason N Gorevic | CEO | Sell | 5,000 | $15.01 | $75,050.00 | 932,258 | |
| 3/17/2016 | Dana G Jr. Mead | Director | Buy | 10,000 | $10.65 | $106,500.00 | 90 | |
| 9/10/2015 | William H Frist | Director | Buy | 4,500 | $22.54 | $101,430.00 | 4,500 | |
(Data available from 1/1/2013 forward)
Teladoc (NYSE TDOC) News Headlines
| Source: |
|
Teladoc (NYSE:TDOC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Teladoc (NYSE:TDOC) Income Statement, Balance Sheet and Cash Flow Statement
Teladoc (NYSE TDOC) Stock Chart for Sunday, May, 20, 2018
Loading chart…
